Skip to main content

Table 4 Univariate analyses and multivariate analyses for progression-free survival in patients with endometrial carcinoma about clinicopathological features and mesothelin, CA125 expressions

From: Significance of mesothelin and CA125 expression in endometrial carcinoma: a retrospective analysis

Variables

 

Univariate analysis

Multivariate analysis for mesothelin expression

Multivariate analysis for co-expression of mesothelin and CA125

HR

(95% CI)

p-value

HR

(95% CI)

p-value

HR

(95% CI)

p-value

Age

≥ 60 vs. <  60

2.18

(1.50–3.23)

< 0.01

1.79

(1.19–2.72)

< 0.01

1.79

(1.19–2.73)

< 0.01

Histological type

Grade 2 endometrioid carcinoma vs. Grade 1 endometrioid carcinoma

3.37

(1.95–5.96)

< 0.01

2.01

(1.12–3.67)

0.019

2.02

(1.12–3.69)

0.018

 

Grade 3 endometrioid carcinoma vs. Grade 1 endometrioid carcinoma

5.17

(2.88–9.36)

< 0.01

2.83

(1.49–5.42)

< 0.01

2.84

(1.50–5.45)

< 0.01

 

Other carcinomas vs. Grade 1 endometrioid carcinoma

8.92

(4.41–12.6)

< 0.01

2.48

(1.34–4.70)

< 0.01

2.49

(1.35–4.72)

< 0.01

FIGO stage

III. IV vs. I. II

7.82

(5.42–11.4)

< 0.01

2.07

(1.08–3.94)

0.028

2.07

(1.07–3.93)

0.029

Depth of myometrial invasion

≥1/2 vs. < 1/2

3.84

(2.66–5.60)

< 0.01

1.59

(0.99–2.58)

0.054

1.57

(0.97–2.55)

0.061

Lymphovascular invasion

Yes vs. No

3.84

(2.62–5.75)

< 0.01

1.94

(1.16–3.25)

0.01

1.94

(1.17–3.25)

0.01

Cervical invasion

Yes vs. No

2.23

(1.50–3.25)

< 0.01

1.44

(0.92–2.24)

0.10

1.45

(0.92–2.45)

0.10

Ovarian metastasis

Yes vs. No

7.48

(4.68–11.5)

< 0.01

1.21

(0.67–2.13)

0.51

1.21

(0.67–2.14)

0.50

Lymph node metastasis

Yes vs. No

5.64

(3.68–8.58)

< 0.01

1.26

(0.70–2.31)

0.44

1.25

(0.69–2.30)

0.45

 

Yes vs. Unevaluated

1.94

(1.20–3.14)

< 0.01

1.27

(0.71–2.31)

0.41

1.27

(0.70–2.31)

0.41

 

Unevaluated vs. No

2.91

(1.84–4.51)

< 0.01

0.96

(0.57–1.68)

0.96

0.98

(0.57–1.67)

0.96

Distant metastasis

Yes vs. No

12.5

(8.14–18.9)

< 0.01

5.89

(3.11–11.1)

< 0.01

5.87

(3.10–11.1)

< 0.01

Peritoneal cytology

Positive vs. Negative

4.42

(3.04–6.38)

< 0.01

1.59

(0.98–2.58)

0.058

1.59

(0.97–2.57)

0.06

Adjuvant therapy

Yes vs. No

2.55

(1.71–3.89)

< 0.01

0.45

(0.26–0.78)

< 0.01

0.45

(0.26–0.78)

< 0.01

Mesothelin expression

Yes vs. No

2.74

(1.91–3.94)

< 0.01

2.14

(1.45–3.16)

< 0.01

   

CA125 expression

Yes vs. No

1.01

(0.68–1.56)

0.92

      

Co-expression of mesothelin and CA125

Yes vs. No

2.86

(2.00–4.12)

< 0.01

   

2.19

(1.49–3.23)

< 0.01

  1. CI confidence interval, HR hazard ratio, CA125 cancer antigen 125, other carcinomas carcinomas including serous carcinoma, clear cell carcinoma, carcinosarcoma, and mixed carcinoma, FIGO International Federation of Obstetrics and Gynecology